Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
IPOs in 2012
After years of deep freeze, signs of life exist in the biopharma IPO market. Sure, the number of IPOs this year (13) was fewer than 2010 (16). Of the 26 launched since 2010, two-thirds now trade at a loss to investors. But some signs of hope exist judging from a smaller percentage of firms discounting on their IPOs this year compared to last year as well as their post-IPO performance. Aveo Pharmaceuticals, which went public in March 2010, has seen its share price zoom 84% since it went public. Of the two most recent biopharma companies to go public, one is trading above its IPO price, while another is unchanged. What will the IPO market look like next year?